Figure 4
OS of post-progression (A) osimertinib treatment and (B) chemotherapy between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups. bev bevacizumab, TKI tyrosin kinase inhibitor.
Figure 4 | Scientific Reports
OS of post-progression (A) osimertinib treatment and (B) chemotherapy between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups. bev bevacizumab, TKI tyrosin kinase inhibitor.
